Gene therapies’ second act: Scaling sustainable modalities for the future

With gene therapies moving beyond proof of concept, the sector faces the challenge of transforming bespoke processes into reliable, cost-effective, and sustainable manufacturing systems. This discussion brings together industry leaders to examine next-generation strategies for production, delivery, and lifecycle management that balance innovation with operational efficiency. 

Key takeaways:

• Analyze key factors driving the evolution of gene therapy from pilot to platform scale 

• Discuss innovations in vector manufacturing and supply chain optimization 

• Evaluate approaches to reduce the cost of goods while maintaining quality and potency 

• Explore models for sustainable commercialization and global patient access 

• Identify regulatory and technical enablers for long-term scalability